MRI Scan for MS (Multiple Sclerosis)

Multiple sclerosis (MS) affects around 150,000 people in the UK — the highest rate in the world per capita. It is a chronic autoimmune condition where the immune system attacks the myelin sheath (protective covering) around nerve fibres in the brain and spinal cord, causing inflammation, demyelination, and eventually nerve damage. MRI is the single most important test for diagnosing MS, monitoring disease activity, and tracking treatment response. Without MRI, modern MS diagnosis and management would be impossible.

If you are experiencing unexplained neurological symptoms — visual problems, numbness, tingling, weakness, balance issues, or cognitive changes — and MS is a concern, an MRI of the brain and spine is the essential first step.

Understanding Multiple Sclerosis

MS damages the myelin sheath and, over time, the nerve fibres themselves. This disrupts the transmission of electrical signals in the brain and spinal cord, causing many different neurological symptoms.

Types of MS

• Relapsing-remitting MS (RRMS) — the most common type (85% of initial diagnoses). Characterised by attacks (relapses) of new or worsening symptoms, followed by periods of partial or complete recovery (remission).
• Secondary progressive MS (SPMS) — develops from RRMS over time. Gradual worsening of disability with or without relapses. Around 65% of people with RRMS eventually develop SPMS.
• Primary progressive MS (PPMS) — around 10-15% of MS cases. Gradual worsening of disability from the outset, without distinct relapses.

Common Symptoms

• Optic neuritis — inflammation of the optic nerve, causing painful, blurred, or lost vision in one eye. The presenting symptom in 20-25% of MS cases.
• Numbness or tingling — often in the face, arms, legs, or trunk. May follow a dermatomal pattern.
• Weakness — leg weakness is common, particularly with spinal cord lesions.
• Balance and coordination problems — cerebellar lesions cause ataxia.
• Fatigue — affects around 80% of MS patients. Often the most disabling symptom.
• Lhermitte's sign — an electric shock sensation down the spine on neck flexion, caused by cervical cord lesions.
• Bladder and bowel dysfunction — very common in established MS.
• Cognitive changes — affect around 50% of patients. Memory, processing speed, and attention.

How MRI Diagnoses MS

MRI is the cornerstone of MS diagnosis, used alongside the McDonald Criteria (revised 2017). The criteria require evidence of damage in multiple parts of the CNS (dissemination in space) at different times (dissemination in time).

What MS Lesions Look Like on MRI

• White matter lesions — appear as bright spots on T2-weighted and FLAIR sequences. In MS, these typically have characteristic locations:
  • Periventricular — around the ventricles (fluid-filled spaces in the brain). Classic for MS. Often oval-shaped and perpendicular to the ventricles ("Dawson's fingers").
  • Juxtacortical/cortical — at the junction between grey and white matter, or within the cortex itself. Cortical lesions are harder to detect but increasingly recognised.
  • Infratentorial — in the brainstem and cerebellum (below the tentorium).
  • Spinal cord — typically short-segment lesions (less than 2 vertebral segments long), peripheral within the cord, in the cervical or thoracic regions.
• Gadolinium-enhancing lesions — lesions that light up after contrast injection are "active" — they represent recent inflammation with blood-brain barrier breakdown. Enhancement typically lasts 2-8 weeks. The presence of enhancing and non-enhancing lesions on the same MRI can satisfy "dissemination in time" criteria.
• T1 "black holes" — chronic, dark lesions on T1-weighted images, representing areas of severe demyelination and axonal loss. These correlate with permanent disability.
• Brain atrophy — accelerated brain volume loss occurs in MS. Newer quantitative MRI techniques can measure this, and it is increasingly used to monitor treatment effectiveness.

MRI Protocol for MS

A full MS MRI protocol includes:

• Brain MRI — T2-weighted, FLAIR, T1-weighted (pre- and post-contrast), DWI. The FLAIR sequence is the most sensitive for periventricular and juxtacortical lesions.
• Spinal cord MRI — T2-weighted sagittal, STIR, T1 post-contrast. Cervical cord is imaged in all suspected MS cases. Thoracic cord may be added. Spinal cord lesions are found in 80-90% of MS patients.

Total scan time: 45-75 minutes for brain and spine together.

What MRI Cannot Show

• A definitive MS diagnosis from imaging alone — white matter lesions can be caused by migraine, small vessel disease, vasculitis, neuromyelitis optica (NMO), and other conditions. The clinical picture, MRI pattern, CSF analysis, and other tests together establish the diagnosis.
• Symptom severity — the relationship between lesion load on MRI and clinical disability is imperfect (the "clinico-radiological paradox"). Some people with many lesions have mild symptoms; others with fewer lesions are more disabled.
• Cortical lesions (reliably) — standard MRI misses many cortical lesions. Double inversion recovery (DIR) and phase-sensitive inversion recovery (PSIR) sequences improve detection but are not universally available.

The Diagnostic Pathway

1. Clinical assessment — neurologist reviews symptoms, performs neurological examination.
2. MRI brain and spine — looking for characteristic lesion pattern.
3. Lumbar puncture — CSF analysis looking for oligoclonal bands (present in around 90% of MS patients but absent from blood). Supports the diagnosis, particularly when MRI findings are borderline.
4. Visual evoked potentials (VEP) — measures the electrical response of the brain to visual stimulation. Slow conduction suggests previous optic nerve demyelination.
5. Blood tests — to exclude other conditions that mimic MS: vitamin B12, thyroid function, ANA, anti-aquaporin-4 antibodies (to rule out NMO), and others.

Treatment Pathways

• Disease-modifying therapies (DMTs) — the mainstay of RRMS treatment. Over 15 DMTs are now available in the UK, ranging from injectable (interferon beta, glatiramer acetate) to oral (dimethyl fumarate, teriflunomide, fingolimod, siponimod, cladribine) to infusion-based (natalizumab, ocrelizumab, alemtuzumab). Treatment aim: reduce relapse frequency and delay disability progression.
• Relapse treatment — high-dose corticosteroids (typically methylprednisolone 500mg-1g IV for 3-5 days or oral equivalent) to shorten relapse duration.
• Symptom management — physiotherapy, occupational therapy, speech therapy, bladder management, fatigue management, psychological support.
• Monitoring — annual or more frequent MRI to assess for new or enlarging lesions. New lesions despite treatment suggest the DMT may need escalating.
• PPMS — ocrelizumab is the only DMT currently approved for PPMS with evidence of inflammatory activity.

UK Statistics

• Around 150,000 people in the UK have MS
• The UK has one of the highest rates of MS in the world
• Average age of diagnosis: 30-40 years
• Women are 2-3 times more likely to be diagnosed with MS than men
• Scotland has the highest MS prevalence in the UK (approximately 1 in 500)
• Average time from first symptom to diagnosis has decreased from 5 years to around 1-2 years with improved MRI availability and the McDonald Criteria

Frequently Asked Questions

Related Articles

• MRI Scan for Brain Tumours
• MRI Scan for Headaches and Migraines
• MRI for Epilepsy
• MRI Scan for Dizziness and Vertigo